Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400588 · ClinicalTrials.gov registry record · Phase 2
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
A Phase 2 study of Obesity and Weight Loss, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 17
- Study locations
NCT07400588: Recruiting Phase 2 study of Obesity and Weight Loss, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
NCT07400588 is a Phase 2 study of Obesity and Weight Loss that is actively recruiting participants, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 50 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07400588, a Phase 2 study of Obesity and Weight Loss, is actively recruiting participants, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aleniglipron
Study Locations (17)
Texas
- Research Site - Austin
- Research Site - Austin
- Research Site - DeSoto
- Research Site - Houston
- Research Site - Mesquite
- Research Site - San Antonio
- Research Site - San Antonio
- Research Site - San Antonio
- Research Site - Tomball
California
- Research Site - Lake Forest
- Research Site - Lomita
Tennessee
- Research Site - Chattanooga
- Research Site - Knoxville
Alabama
- Research Site - Anniston
Missouri
- Research Site - Hazelwood
Ohio
- Research Site - Columbus
South Carolina
- Research Site - Moncks Corner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT07400588 shows while recruiting
NCT07400588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07400588 lists 17 locations in 7 states (Texas, California, Tennessee).
Frequently Asked Questions
What is clinical trial NCT07400588 about?
NCT07400588 is a clinical study titled "Aleniglipron Phase 2 in Type 2 Diabetes Mellitus". The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
What is the current status of trial NCT07400588?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-12-01. Estimated completion is 2026-11.
What conditions does trial NCT07400588 study?
This clinical trial studies the following conditions: Obesity, Weight Loss, Obese, Obesity Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT07400588?
The interventions under investigation include: Placebo (DRUG), Aleniglipron (DRUG).
Who is sponsoring clinical trial NCT07400588?
This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400588 being conducted?
This trial has 17 study locations across Alabama, California, Missouri, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07400588's enrollment target sits among peer trials
50 714th of 1053 higher than 324 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI